首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備

市場調查報告書

商品編碼

1736763

全球電子藥物傳輸系統市場規模（按類型、適應症、區域覆蓋範圍和預測）

Global Electronic Drug Delivery Systems Market Size By Type (wearable infusion pumps, Autoinjectors, injection pens), By Indication(diabetes, multiple sclerosis, cardiovascular disease), By Geographic Scope And Forecast

出版日期: 2025年05月06日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

電子藥物傳輸系統市場規模及預測

電子藥物輸送系統市場規模預計在 2024 年達到 105.7 億美元，到 2032 年將達到 192.6 億美元，在 2026-2032 年預測期內的複合年成長率為 7.79%。

各種慢性病的高發生率，以及易患心血管和呼吸系統疾病的老年患者人數的不斷增加，是預測期內推動市場需求的關鍵因素。電子藥物輸送系統市場報告對市場進行了全面的評估，包括關鍵細分市場、趨勢、市場促進因素、限制因素、競爭格局以及影響市場的關鍵因素。

定義電子藥物傳輸系統的全球市場

電子給藥系統是一種智慧的、電子操作的給藥設備，適用於居家醫療。這些設備為傳統設備增添了價值，提高了給藥的便利性、便利性和便攜性。此外，這些系統在醫院和其他臨床環境中也具有寶貴的優勢。電子給藥系統可以加速糖尿病、心血管疾病和呼吸系統疾病等慢性疾病的管理。

目前，各種技術正在與計算工具相結合，以創新藥物輸送系統，例如電子藥物輸送系統。電子藥物輸送系統已為醫療專業人員、看護者和患者帶來了許多益處，包括藥物治療。穿戴式輸液幫浦、可注射胰島素筆、電子自動注射器、電子吸入器等是市面上現有的一些電子藥物輸送系統。及時正確地注射胰島素是糖尿病患者最關心的問題，而電子胰島素筆可以幫助他們。

全球電子藥物傳輸系統市場概況

市場的主要促進因素包括糖尿病、氣喘和心血管疾病等慢性疾病的日益流行，以及智慧給藥系統技術的發展進步。與傳統給藥方式相比，電子給藥系統具有許多優勢，例如效率更高、耗時更少、副作用更小以及患者可自行給藥，這些優勢預計將推動全球市場的成長。電子給藥系統確保藥物在患者體內正確輸送。電子給藥系統有助於提醒患者註意服藥習慣，並提供正確的用藥指導。

輸液幫浦新藥配方的核准將推動成人糖尿病護理，帶來新的治療方案。此外，智慧型穿戴式輸液幫浦可讓患者無線連接到智慧型手機應用程式，使醫療保健專業人員能夠追蹤患者數據並根據個人需求制定個人化治療方案。用於糖尿病管理的聯網自動注射器的推出預計將推動市場成長。自動注射器和電子幫浦是慢性疾病患者用於小劑量給藥的主要設備。上述因素正在推動全球對電子藥物輸送系統的需求。

然而，系統高成本、維護需求高、替代給藥方式的可用性低以及低收入國家缺乏相關認知度，將限制全球電子給藥系統市場的發展。此外，自動幫浦存在技術故障風險，可能導致劑量錯誤，進而引發藥物不良反應。這可能會阻礙市場成長。技術進步帶來了自主給藥技術，主要是輸液幫浦和自動注射器，這些技術適用於大容量和高黏度生技藥品，為企業創造了潛在的市場機會。

The high prevalence of various chronic disorders and increase in the geriatric patient pool susceptible to cardiovascular and respiratory diseases are the major drivers that propelled the market's demand in the forecast period. The Global Electronic Drug Delivery Systems Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Electronic Drug Delivery Systems Market Definition

These are electronically enabled, smart drug delivery devices are well suited to home care settings. These devices add value to traditional instruments and improve ease of administration, convenience, and portability. However, these systems offer valuable advantages within hospitals and other clinical settings. Electronic drug delivery systems rapidly manage chronic ailments, including diabetes, cardiovascular diseases, respiratory disorders, and other applications.

Nowadays, different technologies are being merged with computation tools to innovate drug delivery systems such as electronic drug delivery systems. It offers several benefits to patients, which include medical professionals, caregivers, and drug regimens. Wearable infusion pumps, injectable insulin pens, electronic autoinjectors, and electronic inhalers are some of the electronic drug delivery systems available in the market. Timely and appropriate insulin dosing are critical concerns in diabetes patients, and electronic insulin pens can help patients.

Global Electronic Drug Delivery Systems Market Overview

The market's significant factors include the increasing prevalence of chronic diseases, such as diabetes, asthma, cardiovascular disease, and technological advancements in developing smart drug delivery systems. Several advantages such as improved efficiency, lesser time consumption, minimum side effects, and self-administered therapy for patients offered by electronic drug delivery systems over conventional drug delivery methods are expected to boost the market's growth globally. Electronic drug delivery systems ensure whether the medications are correctly delivered to the patient's body or not. It helps remind the patients about their drugs intake routine and provides appropriate guidance on using their medications.

Approvals of novel drug formulations in infusion pumps allow a novel treatment option, advancing diabetes care in adults. Moreover, the smart wearable infusion pumps allow the patients to connect to smartphone apps wirelessly. This enables healthcare professionals to track patient data and tailor specific therapies as per individual requirements. The launch of connected autoinjectors for the management of diabetes is expected to drive market growth. Autoinjectors and electronic pumps are the primary devices used in chronic diseases to deliver smaller doses. The factors mentioned above have augmented the demand for electronic drug delivery systems globally.

However, the high cost of systems, the need for maintenance, the availability of alternative modes of drug delivery, and lack of awareness in low-income countries will restrict the global Electronic Drug Delivery Systems Market. In addition, automated pumps may have risks of the wrong dosage with technical glitches and might lead to adverse drug reactions. This may hinder the market growth. Technological advancements allow accessible self-administration technologies, mainly in infusion pumps and autoinjectors that help in large-volume and high-viscosity biologic drugs, which have created a potential market opportunity for the companies.

Global Electronic Drug Delivery Systems Market: Segmentation Analysis

The Global Electronic Drug Delivery Systems Market is Segmented on the basis of Type, Indication, and Geography.

Electronic Drug Delivery Systems Market, By Type

Wearable Infusion Pumps
Autoinjectors
Injection Pens
Inhalers

Based on Type, the market is bifurcated into wearable infusion pumps, autoinjectors, injection pens, and inhalers. Wearable infusion pumps hold the largest market share. The segment will retain its dominant position throughout the forecast period as these pumps are widely used for diabetes management. The injection pen segment is likely to register the fastest CAGR. The approval for injection pens to treat diabetes, offering a portable and convenient option, is expected to increase the segment's market share over the forecast period.

Electronic Drug Delivery Systems Market, By Indication

Diabetes
Multiple Sclerosis
Cardiovascular Disease
Others

Based on Indication, the market is bifurcated into diabetes, multiple sclerosis, cardiovascular disease, and others. The diabetes segment dominates the market due to the high prevalence rate of diabetes among other chronic diseases worldwide and rising adoption of smartphone apps, easy availability of devices like insulin pumps and injection pens by major market players by market players compared to other electronic drug delivery systems.

Electronic Drug Delivery Systems Market, By Geography

North America
Europe
Asia Pacific
Rest of the world
On the basis of regional analysis, the Global Electronic Drug Delivery Systems Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The largest share in the market will be dominated by North America. The increased incidence of target diseases, a rise in the patient population, favorable remuneration policies, and the launch of advanced Electronic Drug Delivery Systems by significant players are attributed to the increase in market revenue.

Key Players

The "Global Electronic Drug Delivery Systems Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Gerresheimer AG, Amgen, Novo Nordisk, Bayer AG, Medtronic plc, Insulet Corporation, AstraZeneca, Tandem Diabetes Care, Merck Group, and United Therapeutics Corporation.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

1 INTRODUCTION OF GLOBAL ELECTRONIC DRUG DELIVERY SYSTEMS MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL ELECTRONIC DRUG DELIVERY SYSTEMS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porter Five Force Model
4.4 Value Chain Analysis

5 GLOBAL ELECTRONIC DRUG DELIVERY SYSTEMS MARKET, BY TYPE

5.1 Overview
5.2 Wearable Infusion Pumps
5.3 Autoinjectors
5.4 Injection Pens
5.5 Inhalers

6 GLOBAL ELECTRONIC DRUG DELIVERY SYSTEMS MARKET, BY INDICATION

6.1 Overview
6.2 Diabetes
6.3 Multiple Sclerosis
6.4 Cardiovascular Disease
6.5 Others

7 GLOBAL ELECTRONIC DRUG DELIVERY SYSTEMS MARKET, BY GEOGRAPHY

7.1 Overview
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.2.3 Mexico
7.3 Europe
- 7.3.1 Germany
- 7.3.2 U.K.
- 7.3.3 France
- 7.3.4 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Rest of Asia Pacific
7.5 Rest of the World
- 7.5.1 Middle East and Africa
- 7.5.2 Latin America

8 GLOBAL ELECTRONIC DRUG DELIVERY SYSTEMS MARKET COMPETITIVE LANDSCAPE

8.1 Overview
8.2 Company Market Ranking
8.3 Key Development Strategies

9 COMPANY PROFILES

9.1 Gerresheimer AG
- 9.1.1 Overview
- 9.1.2 Financial Performance
- 9.1.3 Product Outlook
- 9.1.4 Key Developments
9.2 Amgen
- 9.2.1 Overview
- 9.2.2 Financial Performance
- 9.2.3 Product Outlook
- 9.2.4 Key Developments
9.3 Novo Nordisk
- 9.3.1 Overview
- 9.3.2 Financial Performance
- 9.3.3 Product Outlook
- 9.3.4 Key Developments
9.4 Bayer AG
- 9.4.1 Overview
- 9.4.2 Financial Performance
- 9.4.3 Product Outlook
- 9.4.4 Key Developments
9.5 Medtronic plc
- 9.5.1 Overview
- 9.5.2 Financial Performance
- 9.5.3 Product Outlook
- 9.5.4 Key Developments
9.6 Insulet Corporation
- 9.6.1 Overview
- 9.6.2 Financial Performance
- 9.6.3 Product Outlook
- 9.6.4 Key Developments
9.7 AstraZeneca
- 9.7.1 Overview
- 9.7.2 Financial Performance
- 9.7.3 Product Outlook
- 9.7.4 Key Developments
9.8 Tandem Diabetes Care
- 9.8.1 Overview
- 9.8.2 Financial Performance
- 9.8.3 Product Outlook
- 9.8.4 Key Developments
9.9 Merck Group
- 9.9.1 Overview
- 9.9.2 Financial Performance
- 9.9.3 Product Outlook
- 9.9.4 Key Developments
9.10 United Therapeutics Corporation
- 9.10.1 Overview
- 9.10.2 Financial Performance
- 9.10.3 Product Outlook
- 9.10.4 Key Developments